Enterprise Generative AI Focused on Life Sciences to Bring Life-Saving Drugs to Market Faster
PALO ALTO, Calif., Feb. 6, 2023 /PRNewswire-PRWeb/ -- Huma.AI, a leading healthcare AI company, announced today the launch of its industry-first AI platform for life sciences, which is designed to accelerate the development of life-saving drugs through better usage of their data.
Historically, it has taken 10 years and approximately $2.6 billion to develop a new drug, with a 95% failure rate. This is primarily because 80% of the healthcare/life science data is text-based (unstructured) and siloed in 90-100 disparate data sources. The industry primarily relies on manual curation of data, leaving many critical questions unanswered.
Huma.AI's natural language processing (NLP) platform replaces and automates such manual curation. It connects and searches multiple, disparate, unstructured data sources, returning answers to questions in seconds.
Huma.AI's industry-first generative AI platform for enterprises leverages existing large language models to surface previously unknown intelligence. Going beyond ChatGPT, it analyzes private enterprise data from multiple sources and its "expert-in-the-loop" approach leads to the highest accuracy possible. Use cases include medical affairs (tell me what I don't know), clinical development (better trial design), post market surveillance (systematic literature review and state-of-the-art appraisal) and real-world evidence (patient journey).
"ChatGPT is one of the fastest adopted AI tool in history. It is incredibly useful for general purpose, but not yet adequate at handling complex life science data. We have been working with OpenAI for quite some time to address that," said Huma.AI co-founder and CEO Lana Feng, Ph.D., who previously worked at Novartis Oncology Business Unit to establish international partnerships for their precision medicine programs. She joined Novartis through its acquisition of Genoptix where she built its BioPharma division from zero to $45 million in five years by creating alliances with pharmaceutical companies and providing companion diagnostics development for targeted cancer therapies.
"Huma.AI starts where ChatGPT ends," said Greg Kostello, co-founder and CTO of Huma.AI and author of Huma.AI's NLP granted patent with 25 claims.
Kostello, whose experience also includes contributions to Apple Computer, was previously the CEO for a SaaS Platform used by Cisco, ESPN and NASA, managing petabytes of data. He boasts a 35-year career dedicated to architecting and managing technology systems that solve complex data and business problems. He also worked with video enabling technology at three startups, one acquired by Facebook, EVP of Technology at MP3.com, was President of VUNet Technologies, co-founded a startup acquired by Netscape, and was a team leader that built the core engine for Firefox.
Huma.AI's generative AI platform is highly accurate and validated by global pharmaceutical customers showing it has performed better than human experts.
Customers have commented: "We thought the analysis was written by an expert" and "We thought this kind of output from AI was a pipe dream."
Attached is a PDF documenting customer use cases.
Huma.AI will have a presence at the Clinical Operations Conference-SCOPE 2023 in Orlando, Florida from February 6-9, 2023. SCOPE Summit has driven innovation in clinical trials and digital health for 14 years.
About Huma.AI
Co-founded by Lana Feng Ph.D. and Greg Kostello, Huma.AI is a leading generative AI company offering a powerful and user-friendly NLP platform that turns life science domain experts into their own data scientists. The name Huma means human plus machine where humans always come first. Its transformative, human-centric AI platform has garnered tremendous industry recognition, and Huma.AI currently works with many pharmaceutical and medical device and IVD companies across the globe. Learn more at https://huma.ai.
###
Media Contact
Frank Tortorici, Marketing Maven Public Relations, Inc., 19088758908, [email protected]
SOURCE Huma.AI
Share this article